SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : HEB, Hemispherx Biopharma (AMEX)NEW -- Ignore unavailable to you. Want to Upgrade?


To: Graham Marshman who wrote (63)11/17/1997 11:25:00 PM
From: MarcG  Read Replies (1) | Respond to of 857
 
NEWS on HEB after the bell.

biz.yahoo.com

HEB's loss per share declines while revenues soar. The sales increase is due to the expansion of CFS and AIDS trials
in Belgium, Canada, and the U.S., as well as FDA approved cost recovery program.

MG:



To: Graham Marshman who wrote (63)11/18/1997 1:28:00 PM
From: Linda Kaplan  Read Replies (1) | Respond to of 857
 
Gee. Do you own that stock?

Linda